AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30

$6.36+0.00 (0.00%)

Close on Nov 13, 2026Market cap $159.00KP/E –Yield –

AgomAb Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -€59.06M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-€59.06M	–
FY2024	Dec 31, 2024	-€47.71M	–
FY2023	Dec 31, 2023	-€31.09M	–

See a number that looks wrong?